Ernexa Therapeutics Inc.

NASDAQ: ERNA · Real-Time Price · USD
1.23
0.05 (4.24%)
At close: Sep 16, 2025, 2:06 PM

Ernexa Therapeutics Cash Flow Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Net Income
-44.54M -21.67M -24.58M -122.31M
Depreciation & Amortization
1.64M 1.12M 497K 459K
Stock-Based Compensation
1.52M 1.24M 2.94M 5.24M
Other Working Capital
-2.15M 254K 1.94M -1.69M
Other Non-Cash Items
27.52M 1.01M -3.54M 86.12M
Deferred Income Tax
n/a n/a n/a 9.35M
Change in Working Capital
-1.98M -2.12M 3.71M -2.35M
Operating Cash Flow
-15.84M -20.41M -20.98M -23.49M
Capital Expenditures
-369K -19K -297K -154K
Cash Acquisitions
4K n/a 250K -22.71M
Purchase of Investments
n/a n/a n/a n/a
Sales Maturities Of Investments
n/a n/a n/a n/a
Other Investing Acitivies
n/a n/a n/a 119K
Investing Cash Flow
-365K -19K -47K -22.74M
Debt Repayment
5.29M 16.5M -2K -942K
Common Stock Repurchased
n/a n/a n/a n/a
Dividend Paid
-16K -16K -16K -8K
Other Financial Acitivies
-153K -251K -109K 10K
Financial Cash Flow
6.26M 16.56M 19.58M 61.59M
Net Cash Flow
-9.94M -3.87M -1.44M 15.36M
Free Cash Flow
-16.2M -20.43M -21.27M -23.64M